Publications
This list contains core publications from each of our development programs, but it is not comprehensive. If you would like to take a deeper dive in any of our programs, please contact us.
Alvarado et al, AAAAI, March 2025
"Dual Targeting of Mast Cells and TSLP with the Bispecific Antibody CDX-622"
Metz et al, AAAAI, March 2025
"Treatment with Barzolvolimab Improves Urticaria Control and Quality of Life in Patients with Chronic Inducible Urticaria: Phase 2 12 Week Results"
Metz et al, AAAAI, March 2025
"Barzolvolimab Improves Urticaria Control and Quality of Life in Patients with Chronic Spontaneous Urticaria: 52-Week Data"
Maurer et al, ACAAI, October 2024
"Positive Efficacy and Favorable Safety of Barzolvolimab in Chronic Inducible Urticaria: Phase 2 Trial Results"
Metz et al, EADV, September 2024
"Barzolvolimab shows profound efficacy and favorable safety over 52 weeks in patients with Chronic Spontaneous Urticaria"
Maurer et al, EAACI, June 2024
"Barzolvolimab Significantly Improves Angioedema in Patients with Chronic Spontaneous Urticaria (CSU): Results from a Phase 2 Trial"
Maurer et al, AAAAI, February 2024
"Barzolvolimab Significantly Decreases Chronic Spontaneous Urticaria Disease Activity and is Well Tolerated: Top Line Results from a Phase 2 Trial"
Metz et al, WCI, November 2023
"Barzolvolimab Demonstrates Safety and Clinically Meaningful Activity in Moderate-Severe Prurigo Nodularis"
Maurer et al, EADV, October 2023
"Patients With Chronic Spontaneous Urticaria Experience Improvement in Quality of Life When Treated With Barzolvolimab"
Maurer et al, EAACI, June 2023
"Barzolvolimab Demonstrates Clinical Activity in Antihistamine Refractory Cholinergic Urticaria"
Maurer et al, EAACI, June 2023
"Barzolvolimab Demonstrates Clinical Activity in a Multiple Ascending Dose Trial in Chronic Spontaneous Urticaria"
Alvarado et al, AAI, May 2023
"Dual Targeting of Mast Cells and TSLP with a Bispecific Antibody"
Thomas et al, AACR, April 2023
"CDX-585, a Novel Bispecific Antibody Targeting PD-1 and ILT4"
Maurer et al, AAAAI, February 2023
"Safety and Clinical Activity of Multiple Doses of Barzolvolimab, an anti-KIT Antibody, in Patients with Chronic Spontaneous Urticaria"
Maurer et al, GUF, December 2022
"Cold urticaria patients achieve complete response with 1.5 mg/kg barzolvolimab"
Maurer et al, GUF, December 2022
"Barzolvolimab-induced response and mast cell suppression are durable and linked"
Encore: Maurer et al, GUF, December 2022
"Multi-dosed barzolvolimab is effective in chronic spontaneous urticaria"
Encore: Maurer et al, GUF, December 2022
"Mast cell reduction does not impair human cutaneous wound healing"
Maurer et al, Allergy, December 2022
"Anti-KIT antibody, barzolvolimab, reduces skin mast cells and disease activity in chronic inducible urticaria"
Sanborn et al, SITC, November 2022
"Results from a phase 1 study of CDX-1140, a fully human anti-CD40 agonist monoclonal antibody (mAb), in combination with pembrolizumab"
Maurer et al, EAACI, July 2022
"Effects of Multiple Dose Treatment with an Anti-KIT Antibody, CDX-0159, in Chronic Spontaneous Urticaria"
Alvarado et al, Allergy, February 2022
"Anti-KIT monoclonal antibody CDX-0159 induces profound and durable mast cell suppression in a healthy volunteer study"
Encore: Maurer et al, AAAAI, February 2022
"The Anti-KIT Antibody, CDX-0159, Reduces Mast Cell Numbers and Circulating Tryptase and Improves Disease Control in Patients with Chronic Inducible Urticaria"
Vitale et al, SITC 2021, November 2021
"CDX-585, a Bispecific Antibody with Dual Targeting of ILT4 and PD-1 Checkpoint Pathways"
Maurer et al, EADV, September 2021
"CDX-0159, an anti-KIT Antibody, Demonstrates Rapid and Sustained Clinical Response and Improved Quality of Life in Patients with Chronic Inducible Urticaria"
Maurer et al, EAACI, July 2021
"The Anti-kit Antibody, CDX-0159, Reduces Disease Activity and Tryptase Levels in Patients with Chronic Inducible Urticaria"
Sanborn et al, ASCO 2021 Poster, June 2021
"A Phase 1 dose-escalation study of a PD-L1xCD27 bispecific antibody CDX-527 in patients with advanced malignancies"
Vitale et al, AACR 2021 Poster, April 2021
"Simultaneous De-repression of Innate and Adaptive Immune Responses Through Dual Targeting of ILT4 and PD-(L)1 with Bispecific Antibodies"
Yellin et al, SITC 2020 Poster, November 2020
"CDX527-01, a Phase 1 dose-escalation and expansion study of the PD-L1xCD27 bispecific antibody CDX-527 in patients with advanced malignancies"
Sanborn et al, SITC 2020 Poster, November 2020
"CDX1140-01, a Phase 1 dose-escalation/expansion study of CDX-1140 alone (Part 1) and in combination with CDX-301 (Part 2) or pembrolizumab (Part 3)"
Alvarado et al, SITC 2020 Poster, November 2020
"An Axl-targeting Monoclonal Antibody that Inhibits Axl Activity and Potently Stimulates the Innate Immune Response"
Maurer et al, EAACI, June 2020
"CDX-0159, an anti-KIT monoclonal antibody, demonstrates dose-dependent reductions in plasma Tryptase and a favorable safety profile in a Phase 1a healthy volunteer study"
Vitale et al; , Cancer Immunology, Immunotherapy, May 2020
"Development of CDX‑527: a bispecific antibody combining PD‑1 blockade and CD27 costimulation for cancer immunotherapy"
Vitale et al, SITC 2019 Poster, November 2019
"Combining CD27 costimulation and PD-1 blockade into a bispecific antibody improves T cell activation and anti-tumor activity over combination of individual antibodies"
Sanborn et al, SITC 2019 Poster, November 2019
"Phase 1 study of the CD40 agonist monoclonal antibody (mAb) CDX-1140 alone and in combination with CDX-301 (rhFLT3L) in patients with advanced cancers"
Seibel et al, ACAAI, November 2019
"CDX-0159, an anti-KIT monoclonal antibody, as a modulator of mast cell-related diseases"
Wasiuk et al, August 2019
"Conditioning Treatment with a CD27 Antibody Enhances in vivo Expansion and Antitumor Activity of Adoptively Transferred T Cells"
Thomas et al, AACR 2019 Presentation, April 2019
"Preclinical evaluation of the recombinant dendritic cell growth factor CDX-301 (Flt3L), and AST-008, a TLR9 agonist SNA"
Vitale et al, AACR 2019 Poster, April 2019
"CDX-527: A novel bispecific immune-modulating antibody targeting CD27 and PD-L1"
Thomas et al, AACR 2018 Poster, April 2018
"Efficacy of CDX-1140, an agonist CD40 antibody, in preclinical tumor models"
Sanborn et al, AACR 2019 Poster, April 2019
"First-in-human Phase 1 study of the CD40 agonist monoclonal antibody (mAb) CDX-1140 alone and in combination with CDX-301 (rhFLT3L) in patients with advanced cancers: Interim results"
Reardon et al, November 2018
"Anti-CD27 agonist antibody varlilumab in combination with nivolumab for recurrent glioblastoma: Phase 2 Clinical Trial Results"
Sanborn et al, SITC 2018 Poster, November 2018
"Preliminary results from a first-in-human phase 1 study of the CD40 agonist monoclonal antibody (mAb) CDX-1140"
Ohri et al, AACR 2018 Presentation, April 2018
"FLT3 Ligand (CDX-301) and Stereotactic Radiotherapy for Advanced Non-Small Cell Lung Cancer"
Vitale et al, AACR 2018 Poster, April 2018
"Development of novel bispecific immune modulating antibodies"
He et al, ASH 2016 Poster, December 2016
"CDX-1140, A Novel Agonist CD40 Antibody with Potent Anti-lymphoma Activity"
Thomas et al, Society for Immunotherapy of Cancer, November 2017
"Development of CDX-1140, an agonist CD40 antibody for cancer immunotherapy"
Sanborn et al, June 2017
"Clinical Results with Combination of Anti-CD27 Agonist Antibody, Varlilumab, with Anti-PD1 Antibody, Nivolumab, in Advanced Cancer Patients"
Burris et al, Journal of Clinical Oncology, May 2017
"Safety and Activity of Varlilumab, a Novel and First-in-Class Agonist Anti-CD27 Antibody, in Patients With Advanced Solid Tumors"
Sanborn et al, April 2016
"Phase 1 results from the combination of an immune-activating anti-CD27 antibody (varlilumab) in combination with PD-1 blockade (nivolumab): activation across multiple immune pathways without untoward immune-related adverse events"
Vitale et al, SITC 2016 Poster, November 2016
"Functional characterization of CDX-1140, a novel CD40 antibody agonist for cancer immunotherapy"
Marron et al, AACR 2016 Poster, April 2016
"In Situ Vaccine for Low-Grade Lymphoma: Combination of Intratumoral Flt3L and Poly-ICLC With Low-Dose Radiotherapy"
Vitale et al, AACR 2016 Poster, April 2016
"Development and characterization of novel CD40 antibody agonists for cancer immunotherapy"
Jaglowski et al, ASBMT 2016 Poster, February 2016
"Preliminary Safety and Efficacy Data using CDX-301 (Flt3 ligand) as a Sole Agent to Mobilize Hematopoietic Cells Prior to HLA-matched Sibling Donor Transplantation"
He et al, SITC 2015 Poster, November 2015
"The mechanism of anti-tumor immunity induced by varlilumab, a CD27 agonist mAb, is model dependent"
Ramakrishna et al, Journal for ImmunoTherapy of Cancer, August 2015
"Characterization of the human T cell response to in vitro CD27 costimulation with varlilumab"
Learn More(opens/downloads pdf file)Supplemental Data(opens/downloads pdf file)
Thomas et al, AACR 2015 Poster, April 2015
"Synergistic anti-tumor activity of PD-1 signaling blockade and CD27 costimulation correlates with enhanced ratio of effector to regulatory T cells at the tumor site"
Anandasabapathy et al, Bone Marrow Transplantation, April 2015
"Efficacy and safety of CDX-301, recombinant human Flt3L, at expanding dendritic cells and hematopoietic stem cells in healthy human volunteers"
Bullock et al, SITC 2014 Poster, November 2014
"Immune Correlates of Varlilumab (CDX-1127) Treated Cancer Patients are Consistent with CD27 Costimulatory Activity"
Ansell et al, ASCO 2014 Poster, June 2014
"Phase I Evaluation of an Agonist Anti-CD27 Human Antibody (Varlilumab [CDX-1127]) in Patients with Advanced Hematologic Malignancies"
Infante et al, ASCO 2014 Poster, June 2014
"Immunological Activity of an Activating Anti-CD27 Antibody (Varlilumab [CDX-1127]) in Patients with Solid Tumors"
Thomas et al, OncoImmunology, January 2014
"Targeting human CD27 with an agonist antibody stimulates T cell activation and antitumor immunity"
Keler et al, SITC 2013 Poster, November 2013
"Combination Therapies Augment the Anti-Tumor Activity of Agonist CD27 mAb in Human CD27 Transgenic Mouse Models"
Burris, et al, SITC 2013 Poster, November 2013
"A Phase I Study of an Agonist Anti-CD27 Human Antibody (CDX-1127) in Patients with Advanced Hematologic Malignancies or Solid Tumors"
Ansell, Stephen, SITC 2013 Poster, November 2013
"A Phase I Study of an Agonist Anti-CD27 Human Antibody (CDX-1127) in Patients with Advanced Hematologic Malignancies or Solid Tumors"
He et al, Journal of Immunology, September 2013
"Agonist Anti-Human CD27 Monoclonal Antibody Induces T Cell Activation and Tumor Immunity in Human CD27 Transgenic Mice"
Sundarapandiyan et al, AACR 2013 Poster, April 2013
"Characterization of the Response of Human T cells to an Agonistic Anti-CD27 mAb"
Yellin et al, BMT 2013 Presentation, February 2013
"A Phase 1 Trial of the Hematopoietic Growth Factor CDX-301 (rhuFlt3L) in Healthy Volunteers"
Anandasabapathy et al, ASH 2012 Poster, December 2012
"A Phase 1 Trial of the Hematopoietic Growth Factor CDX-301 (rhuFlt3L) in Healthy Volunteers"
Vitale et al, Clinical Cancer Research, May 2012
"Development of a Human Monoclonal Antibody for Potential Therapy of CD27-Expressing Lymphoma and Leukemia"
He et al, AACR 2012 Poster, April 2012
"Appropriate cross-linking is required for co-stimulatory activity of human anti-CD27 antibody in a transgenic mouse model"
He et al, ASH 2011 Poster, December 2011
"Development of a Human Anti-CD27 Antibody with Efficacy in Lymphoma and Leukemia Models by Two Distinct Mechanisms"
Thomas et al, AACR 2011 Poster, April 2011
"Anti-tumor Activity of a Fully Human anti-CD27 Monoclonal Antibody in a Transgenic Mouse Model"
He et al, AACR 2010 Poster, April 2010
"Development of Novel Anti-CD27 Human Antibodies with Therapeutic Potential"